$USNA

Neidig Brent sold $97K of USNA

Neidig Brent (CHIEF COMMERCIAL OFFICER) sold 5,002 shares of USANA HEALTH SCIENCES INC (USNA) at $19.45 on 2026-06-16.

Original reporting
SEC EDGAR · Neidig Brent
Published Jun 18, 2026, 4:14 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 18, 2026, 4:20 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$USNA
Neutral
medium confidence
Mentioned
$USNA
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$USNANeutralLow
01

Why it matters

This disclosure updates the record of officer ownership and may marginally influence sentiment, but it does not provide new operational or financial information about USANA.

02

Market read

Traders may note the insider sale for sentiment monitoring, but there is no fundamental catalyst to drive a re-rating.

03

What to watch

Insider sales often occur for non-informational reasons (taxes, planned expenses, diversification). Without context on compensation, prior sales, or broader insider activity, directional inference is weak.

Relevance 3/10Novelty 5/10Timing: Filed 2026-06-18 (after-hours/market close) for a sale executed 2026-06-16.

Background

The article is a primary-source SEC Form 4 insider transaction for USANA Health Sciences Inc.

Company-level read

Ticker impact

$USNANeutralMedium confidence
Context

USANA insider Form 4 shows CFO Brent Neidig sold 5,002 shares on 2026-06-16 for about $97.3K, leaving 0 shares.

Expected impact

Low likelihood of a sustained price move; any impact is likely short-lived around the filing date.

Evidence & confidence

The filing is a disclosed open-market sale by an officer, but it does not include new company performance, guidance, or material corporate events.

Market effects

Minimal—single-company insider transaction without sector-wide signal.

None indicated.

None indicated.

Counterpoint

The absence of a disclosed 10b5-1 plan could be interpreted as discretionary selling, but the small size and zero remaining shares can also reflect diversification or tax/liquidity needs rather than bearish expectations.

Key entities

  • USANA Health Sciences Inc

    Subject of the Form 4 insider transaction; CFO Brent Neidig sold shares.

  • Brent Neidig

    Chief Commercial Officer who executed the open-market sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$USNAMedAI 8/10

USANA (USNA) Q2 2026 Earnings Call Transcript

USANA (USNA) held its Q2 2026 earnings call. Management said Core Nutritional was stable, with Mainland China showing renewed strength. The company recorded a preliminary $29 million noncash goodwill impairment and $9 million income tax expense on a $19 million pretax loss. USANA ended the quarter with $169 million cash, zero debt, and $20 million free cash flow, and lowered its fiscal 2026 outlook due to HYA DTC marketing and Rise net sales.

$USNAMedAI 8/10

USANA Health Sciences Q2 Earnings Call Highlights

USANA Health Sciences (NYSE:USNA) reported Q2 updates including a $29 million preliminary non-cash goodwill impairment tied to its Hiya reporting unit and $9 million income tax expense on a $19 million pre-tax loss. Management cited about $30 million to $40 million top-line pressure and $4 million to $5 million margin pressure, plus a Rise packaging disruption. USANA ended with $169 million cash and no debt.

$USNAHighAI 9/10

Why Usana Health Sciences Stock Plummeted This Week

Usana Health Sciences (USNA) shares fell about 30% after its Aug. 4 Q2 results missed expectations and guidance disappointed. The company reported non-GAAP EPS of $0.07 on about $223M sales, with sales and profit below analyst averages. It also took a $29M goodwill impairment on Hiya, cut 2024 guidance to an $11M loss and lowered sales to $910M from $925M-$1B.

$USNAHigh

USANA HEALTH SCIENCES INC (USNA): Results of Operations and Financial Condition

USANA HEALTH SCIENCES INC (USNA) filed an SEC Form 8-K — Results of Operations and Financial Condition. USANA Health Sciences Reports Second Quarter 2026 Results Company Continues Evolution to a Diversified, Omnichannel Health and Wellness Business SALT LAKE CITY, August 4, 2026 (BUSINESS WIRE)—USANA Health Sciences, Inc. (NYSE: USNA) today announced financial results for its fisca